Relamorelin, a cutting-edge therapeutic peptide, exhibits remarkable potential in the realm of biomedical science. Specifically designed to address the intricate complexities of gastrointestinal system disorders, this prodigious innovation functions as a highly potent and selective agonist for the prestigious ghrelin receptor.
CAT No: R2017
CAS No: 661472-41-9
Synonyms/Alias: Relamorelin;Relamorelin [INN];Relamorelin [WHO-DD];Relamorelin [USAN:INN];BIM28131;RM131;UNII-BIW199E18V;661472-41-9;BIM-28131;RM 131;RM-131;BIW199E18V;4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-benzothiophen-3-yl)-2-(piperidine-3-carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide;4-Piperidinecarboxamide, 3-benzo(b)thien-3-yl-N-(4-piperidinylcarbonyl)-D-alanyl-D-tryptophyl-L-phenylalanyl-4-amino-;relamorelinum;4-((2S)-2-((2R)-2-((2R)-3-(1-benzothiophen-3-yl)-2-((piperidin-4-yl)formamido)propanamido)-3-(1H-indol-3-yl)propanamido)-3-phenylpropanamido)piperidine-4-carboxamide;4-[(2S)-2-[(2R)-2-[(2R)-3-(1-benzothiophen-3-yl)-2-[(piperidin-4-yl)formamido]propanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]piperidine-4-carboxamide;Relamorelin (USAN/INN);SCHEMBL17513917;DTXCID201517412;GLXC-25336;DA-67147;D10660;
Chemical Name: 4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-benzothiophen-3-yl)-2-(piperidine-3-carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C43H50N8O5S |
M.W/Mr. | 791 |
InChI | InChI=1S/C43H50N8O5S/c44-42(56)43(16-19-45-20-17-43)51-41(55)34(21-27-9-2-1-3-10-27)49-39(53)35(22-29-25-47-33-14-6-4-12-31(29)33)50-40(54)36(48-38(52)28-11-8-18-46-24-28)23-30-26-57-37-15-7-5-13-32(30)37/h1-7,9-10,12-15,25-26,28,34-36,45-47H,8,11,16-24H2,(H2,44,56)(H,48,52)(H,49,53)(H,50,54)(H,51,55)/t28?,34-,35+,36+/m0/s1 |
InChI Key | IPMQOGDSJZQLFX-BIBZJUPHSA-N |
Canonical SMILES | C1CC(CNC1)C(=O)NC(CC2=CSC3=CC=CC=C32)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CC=CC=C6)C(=O)NC7(CCNCC7)C(=O)N |
Isomeric SMILES | C1CC(CNC1)C(=O)N[C@H](CC2=CSC3=CC=CC=C32)C(=O)N[C@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)NC7(CCNCC7)C(=O)N |
1. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.